Tesamorelin vs CJC-1295: Evidence and Differences

Tesamorelin vs CJC-1295 is not a choice between two versions of the same peptide. Both are growth-hormone-releasing hormone (GHRH) analogues that signal the pituitary to release growth hormone. Tesamorelin is a 44-amino-acid molecule with phase 3 outcome data for HIV-associated lipodystrophy. CJC-1295 is built from GHRH(1-29); its DAC form has a small healthy-volunteer pharmacology program showing prolonged GH and IGF-1 changes, not a demonstrated clinical benefit. In practice, tesamorelin has evidence for visceral fat in one narrow population, while CJC-1295 is discussed for general GH-axis support with much more uncertainty.

Tesamorelin vs CJC-1295 at a glance

The molecules start from different lengths

Tesamorelin keeps all 44 amino acids of human GHRH and attaches a trans-3-hexenoyl group to the N-terminal tyrosine. The current Egrifta WR label, updated July 29, 2026, describes that six-carbon modification and the full sequence. The label also reports that tesamorelin stimulates the same GHRH receptor with similar in-vitro potency to endogenous GHRH.

CJC-1295 uses the active first 29 amino acids as its starting point. The FDA's 2024 CJC-1295 review describes substitutions at four positions in that core. In the DAC form, an added reactive group binds albumin after injection and extends exposure. Without DAC, that albumin-binding feature is absent. Naming is inconsistent enough that a prescription should identify the exact form; CJC-1295 no DAC explains why the multi-day figures from DAC research cannot be transferred to a no-DAC preparation.

The shared receptor means both can increase downstream GH and IGF-1. It does not make their duration, evidence or expected outcomes interchangeable.

The evidence is the decisive difference

Tesamorelin has patient-outcome trials in a defined population. A 2010 pooled analysis in The Journal of Clinical Endocrinology & Metabolism combined two phase 3 trials involving 806 adults receiving antiretroviral treatment who had HIV and excess abdominal fat. At 26 weeks, the estimated treatment effect on visceral adipose tissue was a 15.4% reduction versus placebo (Falutz et al., 2010). That number supports the approved indication; it does not establish general weight loss or an anti-aging result.

CJC-1295 has no comparable outcome trial. The small 2006 clinical paper reported two randomized, placebo-controlled ascending-dose trials in healthy adults. With DAC-bearing CJC-1295, estimated half-life was 5.8 to 8.1 days; mean GH rose two- to tenfold for at least six days, and mean IGF-1 rose 1.5- to threefold for nine to 11 days after one injection (Teichman et al., 2006). Those are pharmacokinetic and biomarker findings. The studies did not test visceral fat, sleep, recovery, muscle gain or long-term clinical benefit.

Promise's related product pairs CJC-1295 with ipamorelin, which signals through a different receptor. That pairing has a physiological rationale, but the exact combination does not have a randomized clinical outcome trial.

Dosing rhythm follows formulation, not the category name

The branded tesamorelin label specifies one subcutaneous dose each day. The DAC-bearing CJC-1295 study used weekly or biweekly administration because albumin binding produced multi-day exposure. A no-DAC preparation is a different timing problem, and a CJC-1295/ipamorelin blend adds another active ingredient.

Those facts describe published protocols, not personal instructions. Tesamorelin dosing decisions depend on the prescribed product, clinical goal and monitoring. The CJC-1295/ipamorelin dosing guide explains how the exact CJC form, concentration and paired ingredient shape a schedule. The prescriber sets the actual dose and rhythm.

How a provider frames the choice

Tesamorelin is the evidence-matched discussion when the clinical question is excess visceral abdominal fat in an adult with HIV-associated lipodystrophy. Outside that population, the phase 3 result is indirect evidence. A provider should not turn a narrow visceral-fat trial into a promise about general body weight.

CJC-1295 may enter a conversation about GH-axis support, but the uncertainty is larger. Its human evidence shows that the DAC form can raise GH and IGF-1 for days; it does not show that doing so improves how a person feels or changes body composition. If the product includes ipamorelin, evidence for CJC-1295 alone cannot establish the blend's outcome.

Screening overlaps because both affect the GH/IGF-1 axis. A provider may consider pituitary history, active or previous malignancy, pregnancy, glucose regulation, baseline IGF-1, medications and whether follow-up labs are practical. The Egrifta WR label specifically addresses elevated IGF-1, glucose intolerance and fluid retention.

As of September 2026, compounded tesamorelin is different from FDA-approved Egrifta WR, whose indication is limited to excess abdominal fat in adults with HIV and lipodystrophy; the formulation offered here is not FDA-approved. No CJC-1295 product is FDA-approved for any indication. FDA's current interim-policy page places CJC-1295 among bulk drug substances whose nominations were withdrawn; it is not in the page's current category 2 table (FDA interim-policy page). A licensed provider may still prescribe a compounded formulation when clinically and legally appropriate; that decision is between the patient and the provider.

What makes the comparison clinically useful

The useful question is not which peptide is stronger. It is whether the person's goal matches evidence from an actual patient population, which CJC-1295 form is in the prescription, whether ipamorelin is also present, and what uncertainty the person and provider are prepared to accept. A longer half-life is a pharmacokinetic property, not proof of a better result.

At Promise, a licensed provider reviews every request, and not everyone qualifies. When a prescription is written, the product comes from a licensed U.S. compounding pharmacy with a defined formulation and a clinician accountable for follow-up.